VivoSeq
Other

Endometrioma

0

Pipeline Programs

2

Active Trials

0

Companies Involved

Endometrioma is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

17/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

12

clinical trials

Unknown status4 · 33%
Completed3 · 25%
Withdrawn2 · 17%
Recruiting2 · 17%
Suspended1 · 8%

Trial Activity

12 trials

Estetrol/Drospirenone to Reduce the Average Size of Endometriomas
Recruiting··Phase 4·NCT05837624·21 enrolled
Surgicel Reduces Ovarian Endometriomas Recurrence
Completed··Phase 2·NCT02947724·200 enrolled
NAC Effect on Infertile Women With Endometrioma
Unknown status·RRoyan Institute·Phase 3·NCT05460858·140 enrolled
Effects of Dienogest and Dienogest Plus Estradiol Valerate in Ovarian Endometrioma
Unknown status··Phase 4·NCT03789123·710 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)